Molecular Pathways: PI3K Pathway Targets in Triple-Negative Breast Cancers
Molecular Pathways: PI3K Pathway Targets in Triple-Negative Breast Cancers
复制标题
DOI：
10.1158/1078-0432.ccr-12-0274
复制
发表时间：
2013-07-15
影响因子：
11.5
通讯作者：
Banerji, Shantanu
中科院分区：
文献类型：
--
作者：
Gordon, Vallerie;Banerji, Shantanu
三阴性乳腺癌（TNBC）亚型，临床上定义为缺乏雌激素，孕激素和Her 2受体表达，占每年乳腺癌诊断的10%至15%。目前，有限的治疗选择已显示出超出细胞毒性化疗的临床益处。定义该临床队列和识别亚型特异性分子靶点对于新的治疗开发仍然至关重要。当前的高通量分子分析时代已经揭示了对这些靶点的新见解，并证实了磷酸肌醇3-激酶（PI 3 K）在发病机制中的关键作用。TNBC分子基础的改进知识与开发新的PI 3 K通路特异性抑制剂的努力并行，可能最终产生迫切需要的治疗突破。(C)2013年AACR。
The triple-negative breast cancer (TNBC) subtype, defined clinically by the lack of estrogen, progesterone, and Her2 receptor expression, accounts for 10% to 15% of annual breast cancer diagnoses. Currently, limited therapeutic options have shown clinical benefit beyond cytotoxic chemotherapy. Defining this clinical cohort and identifying subtype-specific molecular targets remain critical for new therapeutic development. The current era of high-throughput molecular analysis has revealed new insights into these targets and confirmed the phosphoinositide 3-kinase (PI3K) as a key player in pathogenesis. The improved knowledge of the molecular basis of TNBC in parallel with efforts to develop new PI3K pathway-specific inhibitors may finally produce the therapeutic breakthrough that is desperately needed. (C) 2013 AACR.